9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The numerous beneficial health outcomes associated with the use of metformin to treat patients with type 2 diabetes (T2DM), together with data from pre-clinical studies in animals including the nematode, C. elegans, and mice have prompted investigations into whether metformin has therapeutic utility as an anti-aging drug that may also extend lifespan. Indeed, clinical trials, including the MILES (Metformin In Longevity Study) and TAME (Targeting Aging with Metformin), have been designed to assess the potential benefits of metformin as an anti-aging drug. Preliminary analysis of results from MILES indicate that metformin may induce anti-aging transcriptional changes; however it remains controversial as to whether metformin is protective in those subjects free of disease. Furthermore, despite clinical use for over 60 years as an anti-diabetic drug, the cellular mechanisms by which metformin exerts either its actions remain unclear. In this review, we have critically evaluated the literature that has investigated the effects of metformin on aging, healthspan and lifespan in humans as well as other species. In preparing this review, particular attention has been placed on the strength and reproducibility of data and quality of the study protocols with respect to the pharmacokinetic and pharmacodynamic properties of metformin. We conclude that despite data in support of anti-aging benefits, the evidence that metformin increases lifespan remains controversial. However, via its ability to reduce early mortality associated with various diseases, including diabetes, cardiovascular disease, cognitive decline and cancer, metformin can improve healthspan thereby extending the period of life spent in good health. Based on the available evidence we conclude that the beneficial effects of metformin on aging and healthspan are primarily indirect via its effects on cellular metabolism and result from its anti-hyperglycemic action, enhancing insulin sensitivity, reduction of oxidative stress and protective effects on the endothelium and vascular function.

          Related collections

          Most cited references267

          • Record: found
          • Abstract: not found
          • Article: not found

          Frailty in Older Adults: Evidence for a Phenotype

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            mTOR Signaling in Growth, Metabolism, and Disease.

            The mechanistic target of rapamycin (mTOR) coordinates eukaryotic cell growth and metabolism with environmental inputs, including nutrients and growth factors. Extensive research over the past two decades has established a central role for mTOR in regulating many fundamental cell processes, from protein synthesis to autophagy, and deregulated mTOR signaling is implicated in the progression of cancer and diabetes, as well as the aging process. Here, we review recent advances in our understanding of mTOR function, regulation, and importance in mammalian physiology. We also highlight how the mTOR signaling network contributes to human disease and discuss the current and future prospects for therapeutically targeting mTOR in the clinic.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

              Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors--elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle--are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes. We randomly assigned 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week. The mean age of the participants was 51 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 34.0; 68 percent were women, and 45 percent were members of minority groups. The average follow-up was 2.8 years. The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence by 58 percent (95 percent confidence interval, 48 to 66 percent) and metformin by 31 percent (95 percent confidence interval, 17 to 43 percent), as compared with placebo; the lifestyle intervention was significantly more effective than metformin. To prevent one case of diabetes during a period of three years, 6.9 persons would have to participate in the lifestyle-intervention program, and 13.9 would have to receive metformin. Lifestyle changes and treatment with metformin both reduced the incidence of diabetes in persons at high risk. The lifestyle intervention was more effective than metformin.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Endocrinol (Lausanne)
                Front Endocrinol (Lausanne)
                Front. Endocrinol.
                Frontiers in Endocrinology
                Frontiers Media S.A.
                1664-2392
                05 August 2021
                2021
                05 August 2021
                : 12
                : 718942
                Affiliations
                [1] 1Department of Medical Education, Weill Cornell Medicine-Qatar , Al-Rayyan, Qatar
                [2] 2Inflammation Research Network and Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology, University of Calgary Cumming School of Medicine , Calgary, AB, Canada
                [3] 3Department of Medicine, University of Calgary Cumming School of Medicine , Calgary, AB, Canada
                [4] 4Departments of Medical Education and Pharmacology, Weill Cornell Medicine-Qatar , Al-Rayyan, Qatar
                Author notes

                Edited by: James Harper, Sam Houston State University, United States

                Reviewed by: Adiv Johnson, Independent researcher, Tucson, AZ, United States; Adam Konopka, University of Wisconsin-Madison, United States; Andrzej Bartke, Southern Illinois University School of Medicine, United States

                *Correspondence: Chris R. Triggle, cht2011@ 123456qatar-med.cornell.edu ; Ibrahim Mohammed, ibm2001@ 123456qatar-med.cornell.edu

                This article was submitted to Endocrinology of Aging, a section of the journal Frontiers in Endocrinology

                Article
                10.3389/fendo.2021.718942
                8374068
                34421827
                e4b32f21-ac9f-41a2-91a8-2bfbd2251189
                Copyright © 2021 Mohammed, Hollenberg, Ding and Triggle

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 10 June 2021
                : 15 July 2021
                Page count
                Figures: 3, Tables: 2, Equations: 0, References: 267, Pages: 24, Words: 14120
                Categories
                Endocrinology
                Review

                Endocrinology & Diabetes
                metformin,aging,healthspan and lifespan,amp-kinase,calorie restriction mimetic,diabetes,cardiovascular and neurodegenerative diseases,cancer

                Comments

                Comment on this article